Goldman Sachs Group Inc. Sells 138,529 Shares of AnaptysBio, Inc. $ANAB

Goldman Sachs Group Inc. reduced its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 33.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 280,577 shares of the biotechnology company’s stock after selling 138,529 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.95% of AnaptysBio worth $5,216,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ANAB. First Light Asset Management LLC grew its stake in shares of AnaptysBio by 433.3% during the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock worth $86,139,000 after acquiring an additional 3,764,720 shares in the last quarter. Caption Management LLC boosted its holdings in shares of AnaptysBio by 106.3% in the 1st quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company’s stock valued at $435,000 after buying an additional 394,634 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of AnaptysBio by 63.1% in the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after buying an additional 305,950 shares during the last quarter. 683 Capital Management LLC acquired a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $3,637,000. Finally, Palo Alto Investors LP boosted its holdings in shares of AnaptysBio by 20.9% in the 1st quarter. Palo Alto Investors LP now owns 1,020,713 shares of the biotechnology company’s stock valued at $18,975,000 after buying an additional 176,742 shares during the last quarter.

AnaptysBio Price Performance

ANAB stock opened at $19.40 on Wednesday. The stock has a market capitalization of $543.20 million, a price-to-earnings ratio of -4.33 and a beta of -0.19. The business’s fifty day moving average price is $22.91 and its two-hundred day moving average price is $21.14. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $39.50.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.50) by $0.16. The firm had revenue of $22.26 million for the quarter, compared to analysts’ expectations of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. Research analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Guggenheim reissued a “buy” rating and issued a $90.00 price objective (up previously from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th. UBS Group reissued a “neutral” rating and issued a $20.00 price objective (up previously from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. HC Wainwright raised AnaptysBio from a “neutral” rating to a “buy” rating and increased their price objective for the company from $22.00 to $38.00 in a report on Wednesday, June 4th. Finally, Wedbush reissued an “outperform” rating and issued a $45.00 price objective on shares of AnaptysBio in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.13.

Insiders Place Their Bets

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total transaction of $493,202.25. Following the transaction, the director owned 4,965 shares in the company, valued at $117,025.05. This trade represents a 80.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 33.50% of the stock is owned by insiders.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.